Altered Bile Acid Profiles in Advanced Chronic Kidney Disease Reveal Gut-Liver-Kidney Axis Insights

Altered handling of bile acids may be a missing piece in how chronic kidney disease (CKD) progresses, suggests a cross-sectional analysis of advanced CKD that profiled dozens of bile acid species in blood and urine. While overall serum concentrations were steady, the molecular mix shifted-implicating the gut-liver-kidney axis in pathways relevant to inflammation, toxin clearance, and metabolic signaling.

Study at a glance

What the analysis found in serum and urine

• Serum total bile acids: no significant difference between advanced CKD and controls, suggesting that overall bile acid load appears stable.
• Serum composition: lower unconjugated bile acids and markedly higher sulfate-conjugated bile acids in advanced CKD, indicating a shift toward forms that are typically involved in detoxification and excretion.
• Urinary excretion: total bile acids and most bile acid subgroups were substantially lower in CKD, consistent with impaired renal handling and reduced capacity to clear these molecules.
• Kidney function associations: higher serum ursodeoxycholic acid, chenodeoxycholic acid, and sulfate-conjugated bile acids tracked with lower eGFR after adjustment for demographics and diabetes, underscoring that the pattern-not just the quantity-of bile acids aligns with reduced kidney function.

Why bile acids matter for kidney health

Bile acids originate in the liver and are extensively modified by the gut microbiota before being reabsorbed and recirculated through the enterohepatic circulation. Beyond supporting digestion and absorption of dietary fats, they act as signaling molecules with roles in metabolic regulation, inflammation, and energy balance. In CKD, dysbiosis and reduced renal clearance can reshape this network, potentially amplifying uremic toxin burden and chronic inflammation. A compositional shift-particularly toward sulfate-conjugated forms-points to adaptive or impaired pathways of detoxification and clearance as kidney function declines, and may intersect with cardiometabolic risk that health systems already monitor closely.

How health systems could use these signals-if validated

The findings raise pragmatic questions for laboratories, clinicians, and payers about whether bile acid signatures could complement today’s CKD tools built around eGFR and albuminuria. Any move from exploratory signal to clinical utility will require coordinated steps across research, regulation, and reimbursement, and alignment with how kidney disease is staged and managed in national and international guideline frameworks.

• Clinical validity
  • Prospective, longitudinal cohorts to test whether bile acid patterns predict outcomes beyond eGFR and albuminuria, including progression to kidney failure and major cardiovascular events.
  • Assessment of stability across diet, medications (such as bile acid sequestrants and common CKD therapies), microbiome variability, and comorbidities like diabetes and hypertension that are highly prevalent in CKD.
• Analytical readiness
  • Standardized liquid chromatography-mass spectrometry methods, reference materials, and inter-lab calibration so that bile acid panels can be compared across centers and over time.
  • Defined pre-analytical handling to minimize variability from collection to storage, including fasting status, timing of sampling, and storage temperature.
• Regulatory pathway
  • In the United States, clinical deployment typically proceeds as a validated test within CLIA-certified laboratories or as an in vitro diagnostic that undergoes review by the U.S. Food and Drug Administration under its in vitro diagnostic and medical device authorities, as outlined in the FDA’s framework for regulating in vitro diagnostics.
  • Clear clinical claims (risk stratification, prognosis, or monitoring) must be supported by evidence that is reproducible and generalizable, including performance across multiple health systems and practice settings.
• Reimbursement and guidelines
  • Coverage decisions hinge on demonstrated improvement in risk classification and patient-relevant outcomes, not just biomarker performance in isolation.
  • Integration into nephrology practice would depend on alignment with contemporary guideline frameworks that prioritize kidney function and albuminuria categories, such as those used in CKD staging by major nephrology societies and public payers.
• Equity and access
  • Diverse enrollment to avoid biomarker performance gaps across age, sex, race and ethnicity, and socioeconomic status, especially given known disparities in CKD detection and outcomes.
  • Access to specialty laboratory capacity so results are not limited to academic centers; regional lab networks and public payers will be central to avoiding new diagnostic divides.
• Workforce and infrastructure
  • Scaling mass spectrometry and bioinformatics expertise in clinical labs, particularly where CKD burden is highest.
  • Data governance for multi-omic integration with renal registries and electronic records, consistent with privacy and security obligations under frameworks such as the U.S. HIPAA health privacy rules.

What this study does-and does not-establish

• Demonstrated
  • In advanced CKD, the mix of bile acids in serum shifts toward sulfate-conjugated species while urinary excretion declines, suggesting altered processing and clearance.
  • Specific bile acids show independent cross-sectional associations with lower eGFR, even after adjustment for basic demographic factors and diabetes.
• Not demonstrated
  • Causation between altered bile acid metabolism and kidney function decline; the analysis provides associations at a single time point, not mechanistic proof.
  • Prognostic performance for predicting CKD progression or hard outcomes such as kidney failure, cardiovascular events, or mortality.
  • Effectiveness of targeting bile acid pathways as a therapeutic strategy in CKD, whether through drugs, microbiome-directed interventions, or diet.
• Key limitations
  • Small sample size and single time-point assessment, limiting power and preventing causal inference.
  • Potential confounding from diet, medications, and microbiome variability not fully characterized or controlled.
  • Generalizability beyond advanced CKD remains uncertain; it is not yet clear whether similar bile acid signatures appear earlier in the disease course.

Signals to monitor as the field evolves

• Whether bile acid panels improve risk stratification when added to eGFR and albuminuria in prospective cohorts, especially in community and primary care settings where CKD is often underdiagnosed.
• Standardization of assays and external quality assessment that enable cross-center comparability and support guideline bodies considering whether to recommend bile acid testing.
• Interventional trials that modulate the gut-liver-kidney axis and report kidney endpoints, with safety surveillance focused on metabolic and hepatic effects, and on interactions with existing CKD therapies.
• Evidence that biomarker-guided care changes clinical decisions in CKD clinics-such as earlier referral, tighter cardiovascular risk control, or prioritization for novel therapies-with attention to equity and affordability.

The takeaway for public health and policy

CKD care is anchored in early detection and risk reduction using well-validated measures. The bile acid patterns identified here illuminate a plausible, biologically coherent pathway that could refine how patients are phenotyped and prioritized for intensive management, particularly as health systems look for ways to intervene earlier in high-risk populations. For health systems and policymakers, the next step is disciplined validation-moving from intriguing molecular signals to practical tools that are accurate, scalable, and fair, and that can be integrated into existing regulatory, reimbursement, and data-governance frameworks without widening existing gaps in kidney care.